Initially, lymphoid cells transformed by v-ab/ or BCR/ABL oncogenes are poorly oncogenic but progress to full transformation over time. Although expression of the oncogene is necessary to initiate and maintain transformation, other molecular mechanisms are thought to be required for full transformation. To determine whether tumor progression in ABL oncogene-transformed lymphoid cells has a genetic basis, we examined whether progression of the malignant phenotype of transformed clones correlates with particular cytogenetic abnormalities. A modified in vitro bone marrow transformation model was used to obtain clonal Abelson murine leukemia virus-transformed B lymphoid cells that were poorly oncogenic. Multiple subclones were then derived from each clone and maintained over a marrow-derived stromal cell line for several weeks. Over time, clonally related Abelson murine leukemia virus-transformed sub-
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The Ph translocation is found in more than 95% of patients with chronic myelogenous leukemia (CML) and in some patients with acute lymphoid leukemia (ALL) or with acute myeloid le~kemia.4.~ Early stages of these malignancies are relatively easy to manage, but they almost invariably progress to a more aggressive leukemia. For instance, CML progresses from a chronic to an acute malignancy during which 80% of the patients show additional chromosomal abnormalities in their leukemic cells6 In ALL, however, chromosome abnormalities that appear in addition to the Ph chromosome tend to be more variable than in CML; still, some specific changes have been associated with a specific prognosi~.~,~ In one unusual case, leukemic cells from a patient with T-cell ALL (T-ALL) camed a Ph chromosome as well as a t( 1 1 ; 14) and were shown to express both BCW ABL and RBTN-2 oncogenes.' Although the t(l1; 14) has only been reported in cases of T-ALL," the Ph chromosome is more frequently associated with B-progenitor ALL." Together, these observations show that, whereas the BCWABL oncogene may be important for cell transformation, other genetic changes can often affect the multistep pathogenesis as well as the type of leukemia that carries the Ph chromosome.
In the mouse, A-MuLV usually induces an acute transformation of pre-B cells. ' clones progressed asynchronously to full transformation. The data show that tumor progression can occur in the absence of detectable cytogenetic changes but, more importantly, that certain cytogenetic abnormalities appear reproducibly in highly malignant subclones. Therefore, three independent subclones showed deletion in a common region of chromosome 13. Other highly malignant cells carried a common breakpoint in the X chromosome, and, finally. two subclones carried an additional chromosome 5. These results are consistent with the hypothesis that ABL oncogenes are sufficient for the initial transformation of cells but that additional genetic events can drive oncogenic progression. These observations further suggest that diverse genetic mechanisms may be able to drive tumor progression in cells transformed with ABL oncogenes. 0 1994 b y The American Society of Hematology.
to grow, and eventually a single clone will become dominant. During the initial period of this clonal selection in vitro, transformed cells display a weak oncogenic phenotype as shown by their dependence on a feeder layer for growth, inefficient growth in agar, and slow formation of lethal lymphomas in mice. However, after several weeks, the cells become highly oncogenic in vivo, grow well in soft agar, and do not require an adherent feeder layer.13"7 These observations suggest that, similar to the BCWABL oncogene in human leukemia, expression of v-abl is necessary but not sufficient for full transformation.
Although the molecular mechanisms that drive multistep progression of v-abl or BCWABL malignancy are unclear, changes in the malignant phenotype of the cells usually are not accompanied by detectable changes in the expression or kinase activity of the ABL ~ncogene.'~.'~ This provides additional evidence that other unknown genetic or epigenetic changes in the cells may be required for malignant progression. In this report, we hypothesize that if oncogenic progression has a genetic basis it would be at least occasionally evident in the appearance of cytogenetic anomalies during tumor progression. Therefore, we examined whether changes in the malignant phenotype correlate with recurring cytogenetic abnormalities. A modified in vitro transformation model was used to obtain clonal, poorly oncogenic, AMuLV-transformed cell lines. Multiple subclones derived from each transformed clone were then allowed to progress to a more oncogenic stage to determine whether oncogenic progression involved nonrandom cytogenetic changes. The results show that tumor progression can occur in the absence of detectable cytogenetic changes but, more importantly, that certain nonrandom cytogenetic abnormalities often appear in highly malignant subclones, analogous to what is observed in human leukemias.
MATERIALS AND METHODS

Viral stocks and BM transformation.
A-MuLV retrovirus was collected from clonal NIH 3T3 fibroblast cell lines that were superinfected with Moloney murine leukemia virus as previously described.Ix BM cells collected from femurs of 4-to 6-week-old, BALB/c female mice were infected with retrovirus in the presence of polybrene for 4 to S hours and then were plated at 10' cells/mL in IO-cm tissue culture dishes over a preestablished adherent feeder layer. The feeder layer consisted of the S17 adherent cell line that was cloned from the stromal layer of a long-term BM culture and that supports the growth of transformed pre-B-lymphoid cells from A-MuLV-infected BM but does not spontaneously give rise to hematopoietic cells." In these BM cultures, pre-B cells that express the v-ah/ oncogene reach a density of 3 to 5 X 10' cells/mL after about 3 weeks (M. Fizzotti and S. Clark, unpublished).
A-MuLV-transformed clones nnd subclones. Five to seven days after infection, A-MuLV-transformed cells were cloned essentially as described by Whitlock et aI.l4 At this time, transformed cells had not begun to emerge from the infected bulk cultures, which allowed us to obtain clones before significant clonal selection had occurred. Different numbers of nonadherent cells from the infected BM cultures were transferred to individual flat-bottom wells in 96-well tissue-culture plates that contained a confluent layer of S17 cells. Once a week, 80% of the media from the wells was removed by aspiration, and the wells were refed with fresh media. After 3 weeks, wells that contained nonadherent cells were counted, and the cells were expanded to 24-well plates and then to IO-cm plates, always over the S17 feeder layer. Several aliquots of nonadherent cells from the expanded cultures were cryopreserved for future analysis. Remaining cells were subcloned in 96-well plates over the S17 feeder layer, expanded as described above, and maintained in continuous culture over the S17 feeder layer or weaned from the S17-adherent cells.
Analysis of the malignant phenotype. A-MuLV-transformed clones and subclones were assayed for their ability to grow in soft agar as previously described."." Briefly, triplicate cultures of 10' to IO5 cells in 0.26% noble agar containing 20% fetal calf serum and 50 pmol/L 2-mercaptoethanol were plated over the S 17 feeder layer, and colonies were counted I O to 14 days later. Cells were also examined for their ability to form lethal tumors in syngeneic mice by injecting 3 X 10' or 2 X IO6 cells intraperitoneally into 6-to 8-week-old BALB/c female mice.
DNA analysis. Proviral integration sites and Ig heavy chain rearrangement were analyzed by DNA blot hybridization of EcoRIdigested cellular DNA. Filters were hybridized with a 2.3-kb Bgl IIHind11 v-ab/ fragment from pAB3sub3" to detect provirus. Blots were then stripped and rehybridized with a genomic fragment from the murine Ig JH region' to measure IgH rearrangement. t Whole BM was infected with A-MuLV and grown for 5 to 7 days on S17 cells in 10-cm plates before cloning. Positive wells that had been seeded with 5 cells/well were expanded over S17, from which clones B and G were chosen for further analysis.
* Clones that were successfully expanded to 10-cm dishes were immediately subcloned in 96-well plates in the presence of S17 feeder cells.
Cytogenetic analysis. Transformed cells were treated with 0.05 mg/mL colcemid for 3 hours, were given a hypotonic shock in 0.075 m o l L KC1 for 20 minutes at 37"C, then were fixed, and washed 3 times with cold methanol-acetic acid (3: l). Chromosomes were trypsin-G-banded according to Seabright" and arranged according to the Committee on Standardized Genetic Nomenclature for Mice" and the recommendations of Nesbitt and F r a~~k e .~~ A clone was defined as two cells having trisomy or a structural change or three cells having monosomy of a particular chromosome.
RESULTS
Cloning and subcloning of A-MuLV-infected BM cells.
Nonadherent A-MuLV-infected BM cells were harvested from short-term S17 cultures, cloned, and expanded as described in the Materials and Methods. Limiting dilution analysis*' of the data, shown in Table I , indicates that about 0.5% of the plated cells could be cloned (data not shown), which means that, even at the highest cell number (45 cells/ well), there was a high probability that each positive well resulted from the proliferation of a single cell. More than half of the clones that arose failed to survive expansion, and others were lost because of contamination. Wells that were successfully expanded to 1 X 106/mL in IO-cm plates (about 2 weeks) were immediately cryopreserved and subcloned in 96-well plates in the presence of the feeder cells.
Multiple subclones were successfully established from clones B and G, and the data in Table 1 show a distinct difference in their subcloning efficiency. Whereas 93% of the wells seeded with one cell from clone B failed to grow after 3 weeks, only 62% of the wells seeded with one clone G cell per well remained negative 1 week after subcloning. Multiple positive wells from each clone were expanded and maintained for several weeks in culture in the presence of the S17 feeder layer. Two subclones from clone B and five subclones from clone G were successfully grown in the presence of the S17 feeder layer. After 14 weeks in culture, the subclones from clone B were weaned from the feeder layer, For personal use only. on November 11, 2017. by guest www.bloodjournal.org From 9.4 -which caused a short crisis period in which many of the cells died, but, after about 2 weeks, rapid proliferation again resumed in the culture. Subclones from clone G were continually maintained in the presence of S17 feeder cells.
To confirm that clones B and G and their subclones were clonally derived, genomic DNA was digested with EcoRI that does not cut within the A-MuLV proviral DNA. The DNA blot was hybridized with a v-abl probe to detect individual proviral integration fragments. The data show that clone B (Fig IB, lane 1) carried a single unique proviral integration site that is shared with each of the subclones (Fig  1 B, lanes 2 through 5) . Clone G also showed a single proviral restriction fragment that was distinct from that observed in clone B (Fig I B, lane 6) . All subclones from clone G shared the same proviral integration fragment showing that they were derived from the original parental clone (Fig 1 B, lanes  7 through I l) . Some subclones, notably G3 (Fig IB, lane  9) . showed additional hybridizing bands that were distinct from the major proviral band, which indicates that proviral reintegration occurred in these cells. Similar levels of expression and activity of the P160 v-abl kinase were observed in the clones and subclones by immunoblot analysis (data not shown), which confirms previous reports that v-abf expres- To determine the lineage of the transformed clones and subclones, the proviral DNA blot was stripped and rehybridized with a JH probe. The data shown in Fig IA show that, in all clones and subclones, both IgH alleles had rearranged. Flow cytometry also showed that all cells expressed B220 (data not shown). These observations show the B-cell origin of the transformants. Clone B and its derivative subclones all shared identical Ig heavy chain rearrangements on both alleles (Fig IA, lanes 1 through 5) , which shows that Ig rearrangement was fixed in the parent clone before subcloning, a pattern that is expected for A-MuLV-transformed pre-B cells from the BM.'" In contrast, clone G (Fig IA,  lane 6) showed multiple submolar hybridizing bands that, along with a clonal proviral integration pattern, indicate that Ig gene rearrangement continued after transformation. Therefore, Clone G is similar to previously described AMuLV transformants from fetal liver that continue DJ rearrangement after transformation." Subclones derived from clone G also showed a wide variety of Ig rearrangement patterns (Fig IA, lanes 7 through 1 l) , which confirms that DJ rearrangement continued after subcloning. Subclones G1 x Clones and subclones were maintained on S17 adherent cells except for subclones B11 and 821, which were weaned from the feeder layer after 14 weeks of culture.
t Total length of time in culture.
* Soft agar colonies were grown over S17 feeder layer.
4
The indicated number of cells were injected intraperitoneally into 3 to 6 syngeneic mice. The numbers represent the mean length of survival in days, and the range is given in parentheses. All animals injected developed lethal lymphoma.
1 Six animals per group. 11 Three animals per group.
# A-MuLV-transformed pre-B-cell clone F7 was maintained for approximately 40 weeks in the absence of S17 cells.
and G3 (Fig lA, lanes 7 and 9) showed multiple Ig rearranged bands, whereas subclones G2, G4 and G5 show predominantly clonal patterns of DJ rearrangement, showing that, in some subclones, Ig gene rearrangement became fixed after the subcloning step.
A-MuLV-transformed subclones show increased malignant growth properties. To compare the malignant phenotype expressed by A-MuLV-transformed clones and their subclones, cryopreserved cells were thawed and recultured on S17 cells, and their ability to grow in soft agar and to form lethal tumors in mice was examined. The data in Table  2 show that, 5 weeks after infection, both clone B and clone G showed limited ability to form agar colonies. However. whereas only 0.5% of clone B cells were able to grow in agar, 14% of clone G cells formed agar colonies. The different abilities of the clones to grow in semisolid media paralleled their respective subcloning efficiencies reported in Table l . Therefore, it appears that clone G was somewhat more oncogenic than clone B. After 14 weeks in culture, subclones B 1 and B2 were weaned from the S 17 feeder layer and designated B 11 and B21, respectively. These, along with three subclones from clone G that had been maintained for 17 to 18 weeks in the presence of S l 7 feeder cells, were also tested for their ability to grow in semisolid media. Data in Table 2 show that all subclones had dramatically improved in their ability to grow in soft agar, yet most were still not quite as efficient at agar-colony formation as a control cell line that had been maintained in continuous culture without a feeder layer for approximately 10 months.
The cell lines were also tested for their ability to form lethal tumors after peritoneal injection into syngeneic animals. All animals that were injected developed lethal tumors, but animals injected with either parental clone B or clone G cells survived the longest (Table 2 ). The subclones showed variable tumorigenic potential. Whereas subclones B2 I and G1 caused death in about half the time required for clones B and G, other subclones such as B 1 1 and G2 were no more efficient than the parental clones at forming lethal tumors. In a parallel experiment, animals injected with 2 X IO" cells from clone B, B 1 I. or B2 1 were killed when disease became evident, and their lymphomas were removed. DNA blot analysis showed that the lymphomas carried the same clonal proviral integration band as that of the inoculated cells (data not shown), which shows that tumors developed from the injected cells rather than from viral spread.
Recurring chromosomal changes correlate with in vitro progression of the mulignant phenotype. Nonrandom chromosome changes that affect known and unknown genes often accompany oncogenic progression of human leukemias and reflect a genetic basis for malignant progression. To determine whether similar chromosome changes correlate with oncogenic progression of murine pre-B lymphocytes transformed with the v-abl oncogene, the full karyotypes of the A-MuLV-transformed clones and their derivative subclones were compared (Fig 2) . The data show that, early after transformation (5 weeks in culture), A-MuLV clones B and G did not carry detectable cytogenetic abnormalities. However, subclones that had been maintained in culture for 17 to 18 weeks often showed minimal cytogenetic changes that gave an overall impression that the chromosomes were fairly stable. In particular, the control cell line, F7, that had been maintained in continuous culture without a feeder layer for about I O months at the time of the analysis showed no detectable cytogenetic abnormalities (data not shown). even though it was highly oncogenic ( Table 2) .
The data in Fig 2 summarize the karyotypic evolution of the subclones and show that certain cytogenetic changes were reproduced in independent lines. Fifty to eighty percent of cells in subclones B I and B2 carried a normal karyotype, whereas the remaining cells carried relatively simple trisomies and/or chromosome deletions. A minor population in subclone B2 that was subsequently lost on further passage also carried a duplication of 2q(B). Cells derived from subclones B1 and B2 by weaning from the feeder layer (B1 1 and B21, respectively) showed more complex cytogenetic changes that were not related to the changes found in B1 or B2. Thus, B 1 1 and B21 either emerged by karyotypic evolution from the major populations of B1 and B2 that carried a normal 40,XX karyotype or were selected from rare, undetectable subpopulations present in B 1 and B2. Interestingly, both cell lines B 1 1 and B2 1 carried unrelated deletions of similar regions of chromosomes 13 and X (Fig 3) . In the case of cell line B 1 I , two distinct populations were observed, one of which was characterized by a deletion of 13(qA4qC I ) and a normal diploid X chromosome, whereas a minor population carried a normal diploid chromosome 13 but had an interstitial deletion of chromosome X(qBqE) (Fig 3A) . In contrast, cell line B21 consisted of a single population that carried deletions in both X(qBqF3) and I3(qAlqB) (Fig 3B) .
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From These observations show that deletions in chromosome 13 and in the X chromosome arose independently in the two subclones of clone B. The karyotype of B21 was examined again after an additional 5 weeks in culture (B21 1) and was found to have evolved from B21 by acquiring additional chromosome changes, in particular, a +de1(2?).
Three independently derived subclones from clone G were examined for cytogenetic changes ( Figs 2B and 4) . As with the cells from clone B, subclones of clone G had acquired balanced translocations, deletions, and simple duplications of chromosomes. Of particular interest is the fact that even though the proviral integration patterns showed that clones B and G were derived from independently infected cells, abnormalities involving chromosomes X and 13 were observed in the subclones derived from clone G and were similar to the changes observed in subclone B cells. The partial karyotype of subclones GI, G2, and G5 show that subclone G1 contained a reciprocal translocation between the X chromosome and chromosome 12 ( Fig 3A) , whereas subclone G2 carried a deletion of chromosome 13 (qA2qA5) as well as an extra copy of chromosome 5 (Fig 3B) . Subclone G5 showed a trisomy of chromosome 5 as its only cytogenetic change (Fig 3C) . It is possible that, because both subclone G2 and G5 carry an extra chromosome 5, they may have evolved from the same minor cell subpopulation present in clone G. Alternatively, it is possible that the trisomy 5 arose independently in both subclones. In one of two highly tumorigenic BCWABL-transformed cell lines, an iso(5q) was observed as the only abnormality (data not shown), which suggests that an extra copy of chromosome 5 may be nonrandom and occur via different mechanisms in ABL-transformed lymphoid cell lines.
DISCUSSION
This report extends previous observations of tumor progression in v-ab/-transformed lymphocyte~"-'~ by showing that different, clonally-related, A-MuLV-transformed cell lines independently progress to full transformation. This is evidenced by the distinct cytogenetic changes found in related subclones and by their different capabilities to form For personal use only. on November 11, 2017. by guest www.bloodjournal.org From lethal tumors. The data also show that, even a short time after infection with A-MuLV, unrelated clones can express different malignant phenotypes. Therefore, clone G appeared to be further along the oncogenic continuum than clone B. Together, these observations show that multiple mechanisms can drive tumor progression in ABL-transformed cells.
The complex pathogenesis of v-cth/ and RCWABL oncogeneinduced leukemias that is evident from this as well as from other ~tudies'~"'~~-" IS . consistent with a model in which the ABL kinase is necessary to initiate and to maintain tnnsformation but is not sufficient to induce the full malignant phenotype. Because others have reported that oncogenic progression occurs in the absence of changes in the ABL kina~e,'~.''' and because we did not detect alteration in P160 v-ah/ expression or kinaTe activity in any of the clones or subclones tested, it is unlikely that altered expression or activity of the v-ah/ kinase contributes significantly to malignant progression. However, to definitively prove that the transformation potential of the v-ah/ oncogene has not changed in highly malignant cells, it will be necessary to compare the transforming ability of virus rescued from poorly versus highly oncogenic cells. Finally, we cannot formally rule out that epigenetic factors may play a significant If true, it would be reasonable to think that at least some genetic changes would be evident through chromosomal abnormalities, and our observations support this hypothesis. As predicted, v-ahl-transformed clones showed a normal karyotype early after transformation, which is consistent with the ABL kinase being sufficient for the initial transformation. Over time, most transformed subclones acquired cytogenetic abnormalities while becoming more malignant, which supports the hypothesis that genetic changes drive tumor progression. Yet, some highly malignant v-ah/-transformed cells that had been maintained for several weeks in liquid culture showed a normal karyotype. However, in such cases, we cannot eliminate the possibility that submicroscopic changes not detectable by karyotype analysis may have occurred in the chromosomes of these cells.
In the present study, the strongest evidence that specific genetic changes drive malignant progression of A-MuLVtransformed lymphoblasts comes from the appearance of independently arising nonrandom chromosomal changes in distinct subclonal populations (summarized in Fig 5) . Three independent subclones (two from clone B and one from clone G) showed structural changes of the X chromosome that point to a common breakpoint near band XqB in all three subclones (Fig 5B) . Figure 5A summarizes the interstitial deletions observed in chromosome 13 of three independent subclones derived from both clones B and G. It may be significant that all three deletions overlapped, giving a least common deleted region at 13(qA4A5). Finally, an additional copy of chromosome 5 was observed in two different subclones. Together, these observations suggest that different nonrandom genetic changes can be associated with tumor progression in this system. It is probable that, as more ARLtransformed cells are examined, additional karyotypic changes will be found to be associated with oncogenic progression.
From the background of recurring cytogenetic changes in human and murine leukemias induced with different ABL oncogenes, certain conclusions can be made regarding the chromosome changes that were associated with progression of A-MuLV transformation. First, it may be significant that trisomy 5 is found in multiple models ofABL-induced leukemia including the highly oncogenic cells transformed with either v-ah/ or RCWARL. Trisomy 5 is also found in AMuLV-transformed lymphoid cells that switch to the macrophage lineage" and in lymphoblastic leukemias induced by a P190 RCWABL transgene.3" Regions of mouse chromosome 5 are syntenic with portions of human chromosomes 4,7q, 12q, 7q, and 13q, of which +4 represents a nonrandom change associated with human ALL.4" The syntenic regions between human chromosome 4 and murine chromosome 5 carry genes for fibroblast growth factor-5, melanoma growth-stimulating activity, a platelet-derived growth factor receptor subunit, KIT, and a homeobox-containing gene,40 any of which could feasibly affect the growth of leukemic lymphoblasts.
The independently arising interstitial deletions of chromosome 13 that we observed showed heterogeneous proximal and distal breakpoints; yet, all three shared a common deleted region in band 13qA near the junction with 13qB ( Fig  5A) . This represents map region 15 to 25 centimorgan (CM) on the consensus genetic linkage map of chromosome 13.41 Several instances of inversions and translocations as well as trisomy and pentasomy of chromosome 13 have been reported in murine leukemia and mammary carcinoma35A143; however, interstitial deletion of chromosome 13 has not been reported as a recurring feature in other murine malignan~i e s .~' Regions of mouse chromosome 13 are syntenic with human chromosomes 7p, 6p, and 5, but most of the common deletion has not been assigned a human synteny.4'
The last recurring change that we observed in progressing A-MuLV-transformed lymphoblasts involved the X chromosome. Two cell lines carried deletion of different portions of Xq, whereas the third clone carried a t(X; 12). As shown in Fig 5B, all of these changes involved a common breakpoint near the junction of XqB-qC that lies at approximately map position 30 on the consensus genetic map, a region that is syntenic with human Xq28.M Although sex chromosome abnormalities are not common and, when observed, usually involve numerical differences only, examples of structural abnormalities in human malignancies do exsquamous cell carcinoma4' and cases of non-Hodgkin's lymphoma4' that show recurring translocations and deletions involving breakpoints at Xq28. Recently, a putative oncogene, ACLI, has been cloned from a T-cell leukemia and mapped to Xq28.49 However, because Xq28 is either deleted or translocated in patients with non-Hodgkin's lymphoma4' it suggests that there may also be a tumor suppressor gene in this region that could also be important in other T-cell malignancies where loss of the X chromosome has been rep~rted.~' Our observation of deletion or translocation in murine lymphoblasts at XqB suggests that a similar gene also may be involved in A-MuLV leukemogenesis.
Results presented here are consistent with the hypothesis that genetic changes are required for ABL-transformed cells to express the fully transformed phenotype. It will be interesting to further compare the cellular and genetic changes associated with oncogenic progression in cells transformed by the relatively weak BCWABL oncogenes versus the more potent v-abl oncogenes. This will allow us to learn whether similar or different pathogenic mechanisms drive progression of pre-B lymphocytes transformed with distinct forms of the ABL kinase. It will also be interesting to compare the genetic changes that occur during in vivo progression of vabl-induced leukemia with what is observed during in vitro progression to determine how closely the in vitro model correlates with in vivo selection of highly malignant cells. Finally, lessons learned from animal models of v-abl-induced and BCRLABL kinase-induced acute lymphoblastic leukemias can be applied to the investigation of the pathogenesis of human Ph' leukemia. In conclusion, we have a model by which karyotypic evolution of clonal ABL-transformed lymphocytes can be correlated with oncogenic progression. The ultimate goal will be to use this model to identify genes that may correlate with distinct clinical prognoses and leukemic relapse in human leukemias. 
